ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0639

Immunological Abnormalities in a SARS-CoV-2-Cytokine Release Syndrome Rheumatology Cohort
Abstract Number: 0640

Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence
Abstract Number: 0641

Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?
Abstract Number: 0642

COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Abstract Number: 0643

Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
Abstract Number: 0644

Characterizations of Cytokine Storm Associated with COVID19
Abstract Number: 0645

Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis
Abstract Number: 0646

“An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television
Abstract Number: 0647

Dual-energy CT versus Ultrasound, Alone or in Combination, for the Diagnosis of Gout: A Diagnostic Performance Study
Abstract Number: 0648

Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis
Abstract Number: 0649

A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report
Abstract Number: 0650

Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout
Abstract Number: 0651

Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares
Abstract Number: 0652

Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
Abstract Number: 0653

Nutrient Content of Gout Flare Trigger Foods

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].